As of Friday close, Checkpoint Therapeutics Inc.’s (NASDAQ:CKPT) stock was up $0.25, moving up 12.69 percent to $2.22. The average number of shares traded per day over the past five days has been 429,740 shares. 2 times new highs have been achieved over the past 5 days, with a $0.0800 gain in that time frame. In the last twenty days, the average volume was 403,210, while in the previous 50 days, it was 267,538.
Since last month, CKPT stock retreated -32.73%. Shares of the company fell to $1.8400 on 08/16/23, the lowest level in the past month. A 52-week high of $14.10 was reached on 01/13/23 after having rallying from a 52-week low of $1.84. Since the beginning of this year, CKPT’s stock price has dropped by -56.56% or -$2.8900, and marked a new high 4 times. However, the stock has declined by -84.26% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
CKPT stock investors should be aware that Checkpoint Therapeutics Inc. (CKPT) stock had its last reported insider trading activity 170 days ago on Mar 02. Oliviero James F III, the CEO, President and Director of the company, disposed of 5,483 shares for $5.00 on Mar 02. It resulted in a $27,415 divestment by the insider. GRAY WILLIAM GARRETT sold 3,591 shares at an average price of $5.00 on Mar 02. The insider now owns 51,374 shares following the transaction. On Feb 27, CEO, President and Director Oliviero James F III sold 5,548 shares at $4.65 apiece. The transaction was valued at $25,798.
Financial Health
In the three months ended June 29, Checkpoint Therapeutics Inc.’s quick ratio stood at 0.20, while its current ratio was 0.20, showing that the company is not able to pay off its debt. Based on annual data, CKPT earned $58.52 million in gross profit and brought in $0.19 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 299.10%. Return on equity (ROE) for the past 12 months was 633.20%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. CKPT’s revenue rose 33.33% during the quarter, while net income inched up to $30000.0. While analysts expected Checkpoint Therapeutics Inc. to report -$0.78 quarterly earnings, the actual figure was -$1.05 per share, beating the consensus estimate by -34.60%. During the quarter, the company generated -$16.2 million in EBITDA. The liabilities of Checkpoint Therapeutics Inc. were 31.61 million at the end of its most recent quarter ended June 29. The value of shareholders’ equity is $21.59 million.
Technical Picture
This quick technical analysis looks at Checkpoint Therapeutics Inc.’s (CKPT) price momentum. With a historical volatility rate of 76.78%, the RSI 9-day stood at 46.04% on 18 August.
With respect to its five-day moving average, the current Checkpoint Therapeutics Inc. price is up by +3.74% percent or $0.0800. At present, CKPT shares trade -34.90% below its 20-day simple moving average and -41.88% percent below its 100-day simple moving average. However, the stock is currently trading approximately -25.25% below its SMA50 and -77.80% below its SMA200.
Stochastic coefficient K was 22.33% and Stochastic coefficient D was 12.29%, while ATR was 0.2200. Given the Stochastic reading of 46.91% for the 14-day period, the RSI (14) reading has been calculated as 43.45%. As of today, the MACD Oscillator reading stands at -0.0700, while the 14-day reading stands at -0.1600.
Analyst Ratings
Checkpoint Therapeutics Inc. (CKPT) has been rated Buy by analysts. According to 0 brokerage firms, CKPT is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Checkpoint Therapeutics Inc. stock as buy, with 5 recommending it as overweight.
With a median target price of $15.00, the current consensus forecast for the stock is $14.00 – $47.00. Based on these forecasts, analysts predict Checkpoint Therapeutics Inc. (CKPT) will achieve an average price target of $24.80.
